Co-Diagnostics, Inc. (CODX)
Nasdaq · Healthcare · Medical Devices
$1.10+1.85%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.7M
- 52-week range
- $0.906 – $46.50
- 52-week change
- −90.53%
- EPS (trailing)
- −$26.14
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $622K (−84.10%)
- Net income
- −$47.0M
- Operating margin
- −8058.8%
- Diluted EPS
- −$35.25
- Free cash flow
- −$29.8M
From the company’s annual report on SEC EDGAR.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Headquarters: Salt Lake City, United States · 115 employees · co-dx.com